Champions Oncology, Inc.

NasdaqCM:CSBR Stok Raporu

Piyasa değeri: US$58.7m

Champions Oncology Yönetim

Yönetim kriter kontrolleri 4/4

Champions Oncology CEO'su Ronnie Morris, Jan2017 tarihinde atandı, in görev süresi 7.83 yıldır. in toplam yıllık tazminatı $ 400.00K olup, şirket hissesi ve opsiyonları dahil olmak üzere 100% maaş ve 0% ikramiyelerden oluşmaktadır. şirketin hisselerinin 6.32% ine doğrudan sahiptir ve bu hisseler $ 3.71M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 13.4 yıldır.

Anahtar bilgiler

Ronnie Morris

İcra Kurulu Başkanı

US$400.0k

Toplam tazminat

CEO maaş yüzdesi100.0%
CEO görev süresi7.8yrs
CEO sahipliği6.3%
Yönetim ortalama görev süresi3.8yrs
Yönetim Kurulu ortalama görev süresi13.4yrs

Son yönetim güncellemeleri

Recent updates

Companies Like Champions Oncology (NASDAQ:CSBR) Can Afford To Invest In Growth

Oct 24
Companies Like Champions Oncology (NASDAQ:CSBR) Can Afford To Invest In Growth

It's A Story Of Risk Vs Reward With Champions Oncology, Inc. (NASDAQ:CSBR)

Jun 14
It's A Story Of Risk Vs Reward With Champions Oncology, Inc. (NASDAQ:CSBR)

Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?

Sep 28
Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?

Champions Oncology Non-GAAP EPS of -$0.02, revenue of $12.9M

Jul 21

We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation

Oct 14
We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation

We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth

Jun 21
We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth

Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?

Apr 09
Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?

Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation

Mar 19
Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation

The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?

Mar 02
The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?

Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?

Feb 04
Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?

Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?

Jan 14
Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?

Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares

Dec 19
Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares

Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results

Dec 16
Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results

Champions Oncology beats on revenue

Dec 14

Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)

Dec 04
Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)

CEO Tazminat Analizi

Ronnie Morris'un ücretlendirmesi Champions Oncology'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jul 31 2024n/an/a

-US$3m

Apr 30 2024US$400kUS$400k

-US$7m

Jan 31 2024n/an/a

-US$10m

Oct 31 2023n/an/a

-US$10m

Jul 31 2023n/an/a

-US$8m

Apr 30 2023US$600kUS$400k

-US$5m

Jan 31 2023n/an/a

-US$3m

Oct 31 2022n/an/a

US$108k

Jul 31 2022n/an/a

US$401k

Apr 30 2022US$800kUS$400k

US$548k

Jan 31 2022n/an/a

US$219k

Oct 31 2021n/an/a

US$391k

Jul 31 2021n/an/a

US$115k

Apr 30 2021US$775kUS$375k

US$362k

Jan 31 2021n/an/a

-US$1m

Oct 31 2020n/an/a

-US$2m

Jul 31 2020n/an/a

-US$1m

Apr 30 2020US$1mUS$394k

-US$2m

Jan 31 2020n/an/a

-US$181k

Oct 31 2019n/an/a

-US$956k

Jul 31 2019n/an/a

-US$995k

Apr 30 2019US$146kUS$146k

US$128k

Jan 31 2019n/an/a

-US$251k

Oct 31 2018n/an/a

US$42k

Jul 31 2018n/an/a

-US$320k

Apr 30 2018US$244kn/a

-US$1m

Tazminat ve Piyasa: Ronnie 'nin toplam tazminatı ($USD 400.00K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 651.15K ).

Tazminat ve Kazançlar: Ronnie 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

Ronnie Morris (58 yo)

7.8yrs

Görev süresi

US$400,000

Tazminat

Dr. Ronnie Morris, M.D. has been Chief Executive Officer at Champions Oncology, Inc. since January 31, 2017. Dr. Morris previously served as the President and a Director of Champions Oncology, Inc. from Oc...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Ronnie Morris
CEO & Director7.8yrsUS$400.00k6.32%
$ 3.7m
David Miller
Chief Financial Officer7.5yrsUS$260.00k0.041%
$ 23.8k
Maria Mancini
Chief Operating Officer1.3yrsVeri yokVeri yok
Arthur Hanson
Vice President of Technology4.5yrsVeri yokVeri yok
Rachel Bunting
Vice President of Global Marketingno dataVeri yokVeri yok
Michael Ritchie
Chief Commercial Officerno dataVeri yokVeri yok
Karin Heidemann
Executive Vice President of Global Scientific Operations3.2yrsVeri yokVeri yok
Marianna Zipeto
Executive Vice President of Commercial1.3yrsVeri yokVeri yok

3.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: CSBR 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Ronnie Morris
CEO & Director14.1yrsUS$400.00k6.32%
$ 3.7m
Scott Tobin
Independent Director13.4yrsUS$93.30k0.22%
$ 129.6k
Joel Ackerman
Independent Chairman of the Board14.1yrsUS$116.62k7.08%
$ 4.2m
David Sidransky
Independent Lead Director17.3yrsUS$85.54k5.64%
$ 3.3m
René Bernards
Scientific Advisorno dataVeri yokVeri yok
Manuel Hidalgo
Scientific Advisorno dataVeri yokVeri yok
Daniel Mendelson
Independent Director11.7yrsUS$85.52k1.46%
$ 858.1k
Harvey Pass
Scientific Advisorno dataVeri yokVeri yok
Philip Breitfeld
Independent Director8.6yrsUS$85.54k0.11%
$ 63.2k
Misti Ushio
Board Observerno dataVeri yokVeri yok
Justin Stebbing
Scientific Advisorno dataVeri yokVeri yok
Robert Brainin
Independent Director3.8yrsUS$82.20k0%
$ 0

13.4yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CSBR 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 13.4 yıldır).